Boston Scientific has released one-year, retrospective data to demonstrate efficacy for its Precision Spectra Spinal Cord Stimulator in treating chronic lower back pain.
St. Jude Medical has gained approval for a quadripolar cardiac resynchronization therapy pacemaker that for the first time incorporates its MultiPoint Pacing technology that's been shown to be better for patients who don't respond to traditional biventrical pacing.
As hospitals scramble to reduce readmissions, or face punishment under the Affordable Care Act's Hospital Readmissions Reduction Program, they are increasingly turning to efficiency-promoting devices like St. Jude Medical's CardioMEMS HF System for monitoring heart failure patients.
Minnesota-based device giant St. Jude Medical is beating the bushes in Malaysia, possibly looking to expand its production and services operations there, Malaysia's New Straits Times reported.
St. Jude Medical snagged FDA approval for its next-generation ablation catheter for atrial fibrillation, bolstering the company's presence in a growing electrophysiology market and strengthening its footprint in the cardiac rhythm management sector.
Amid growing industry concern over the cybersecurity of medical devices, the U.S. government is weighing in on the issue and investigating two dozen cases of suspected cybersecurity flaws in devices and hospital equipment.
St. Jude Medical reported modest gains in third-quarter sales, supported by new products that include its CardioMEMS heart failure monitoring system.
St. Jude Medical has halted implantation of its Portico transcatheter aortic valve replacement due to concerns about reduced valve leaflet mobility arising from the company's U.S. clinical trials. The CE-marked device is intended for patients with severe aortic stenosis who are at high risk or contraindicated for surgical aortic valve replacement.
St. Jude Medical's data dump at the European Society of Cardiology Congress in Barcelona, Spain, was heartening news for the company's products--especially those used to measure a ratio known as fractional flow reserve.
The U.S. Food and Drug Administration has picked up the pace on novel medical device approvals, but this year still may not hit levels seen in 2011 and 2012. During the first six months of 2014, the agency granted 17 premarket approvals, way up from 23 for the entirety of 2013.